PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

EuroGuiDerm 2025 Acne Update: Antibiotic Limits, Hormonal Options

isotretinoinspironolactonecombined oral contraceptivesdoxycyclinelymecyclinebenzoyl peroxidetrifaroteneclascoteroneacne vulgarisantimicrobial stewardshiphormonal therapyclinical practice guidelinewomen's health Women's Health

Background Information

Revamped acne treatment guidelines emphasize isotretinoin and hormonal therapies.

Guidelines update best practices for treating acne, crucial for patient outcomes, especially in women with specific hormonal considerations. Recommendations updated on isotretinoin, systemic antibiotics, hormonal treatments like spironolactone, and new topicals trifarotene and clascoterone. Important for selecting appropriate acne treatments, considering patient groups and safe options during pregnancy; guidelines based on robust evidence. Updated guidelines refine acne treatment strategies with clear indications and safety profiles.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Nast A, Al Wattar BH, Beylot Barry M, Brüggemann H, Bukvić Mokos Z, Caruana DM, Degitz K, Dessinioti C, Dréno B, Driessen RJB, Gollnick H, Hædersdal M, Katoulis A, Läuchli S, Lambert J, Layton AM, Micali G, Ochsendorf FR, Sathyapalan T, Stangeland KZ, Thomsen SF, Töröcsik D, Pennitz A

Citation: Nast A, Al Wattar BH, Beylot Barry M, et al. Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short version. Journal of the European Academy of Dermatology and Venereology : JEADV. 2026;40(7):1162-1172. doi:10.1111/jdv.70331

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →